Drug Development

Listings
  • Anti-CD22 (10F4v3)-SPP-DM1 ADC

    Anti-CD22 (10F4v3)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 15, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (10F4v3) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the c...

  • Anti-CD22 (clone HB22.7)-saporin ADC

    Anti-CD22 (clone HB22.7)-saporin ADC

    Drug Development Shirley (New York) November 15, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone HB22.7) conjugated via a linker to saporin. Saporin is a plant toxin belonging to the ribosome-inactivating protein (RIP) family, a class of toxic enzymes that is widely distrib...

  • Anti-CD22-Mc-VC-PAB-NMS249 ADC

    Anti-CD22-Mc-VC-PAB-NMS249 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone C16) conjugated via a Mc-VC-PAB linker to NMS249. Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release ...

  • Anti-CD22 (clone hu10F4)-MCC-DM1 ADC

    Anti-CD22 (clone hu10F4)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 (clone hu10F4) monoclonal antibody conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...

  • Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

    Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an Anti-CD22 antibody (clone G5/44) conjugated via a AcBut linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. With...

  • Anti-CD22-DIBO-doxorubicin ADC

    Anti-CD22-DIBO-doxorubicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Wi...

  • Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Inotuzumab conjugated via a hydrazone linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Pinatuzumab conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds t...

  • Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Anti-CD22 (Epratuzumab)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins...

  • Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Anti-CD22 (Epratuzumab)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Epratuzumab conjugated via a MC linker to a MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubuli...

  • Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2E-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2E linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is targeted to certa...

  • Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Anti-CD22 (Epratuzumab)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an a Epratuzumab conjugated via a CL2A linker to a SN-38.The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.The SN-38 is targeted to certain...